Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

NCT03452592 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

220

Enrollment

INDUSTRY

Sponsor class

Stopped Indications have been approved for marketing

Conditions

Advanced NSCLC Patients With T790M

Interventions

DRUG: Alflutinib

Sponsor

Allist Pharmaceuticals, Inc.